Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Heindryckx, Femke ^a   Mertens, Koen ^a   Charette, Nicolas ^b   Vandeghinste, Bert ^c   Casteleyn, Christophe ^c   Van Steenkiste, Christophe ^a   Slaets, Dominique ^c   Libbrecht, Louis ^a   Staelens, Steven ^c   Starkel, Peter ^b   Geerts, Anja ^a   Colle, Isabelle ^a   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; CELL PROTEIN; DIETHYLNITROSAMINE; ENDOGLIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACENTAL GROWTH FACTOR; PROTEIN F4 80; UNCLASSIFIED DRUG; VASCULOTROPIN; CARCINOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RESEARCH; CANCER TISSUE; CONTROLLED STUDY; DISEASE MODEL; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; ANIMAL; CHEMICALLY INDUCED DISORDER; LIVER TUMOR; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; CARCINOGENS; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; LIVER NEOPLASMS, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77955702479     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-219     Document Type: Article

References (34)

1. Egeblad M, Ewald AJ, Askautrud HA, Truitt ML, Welm BE, Bainbridge E, Peeters G, Krummel MF, Werb Z. Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis Model Mech 2008, 1:155-167. discussion 165, 10.1242/dmm.000596, 2562195,2562195, 19048079.
2. Bissell MJ, Radisky D. Putting tumours in context. Nature Reviews Cancer 2001, 1:46-54. 10.1038/35094059, 11900251.
3. Gopinathan A, Tuveson DA. The use of GEM models for experimental cancer therapeutics. Dis Model Mech 2008, 1:83-86. 10.1242/dmm.000570, 2562176, 19048065.
4. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 2008, 1:78-82. 10.1242/dmm.000976, 2562196, 19048064.
5. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007, 170:793-804. 10.2353/ajpath.2007.060929, 1864878, 17322365.
6. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2003, 2:S134-139.
7. Swenberg JA, Hoel DG, Magee PN. Mechanistic and statistical insight into the large carcinogenesis bioassays on N-nitrosodiethylamine and N-nitrosodimethylamine. Cancer Res 1991, 51:6409-6414.
8. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009, 136:1134-1144. 10.1053/j.gastro.2009.02.038, 19245868.
9. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, Thorgeirsson SS. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004, 36:1306-1311. 10.1038/ng1481, 15565109.
10. Amarapurkar AD, Vibhav, Kim V. Angiogenesis in liver cirrhosis and hepatocellular carcinoma. Indian J Pathol Microbiol 2008, 51:323-328. 10.4103/0377-4929.42504, 18723951.
11. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Annals of Surgical Oncology 2008, 15:962-971. 10.1245/s10434-007-9730-z, 18236113.
12. Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009, 9:503-509. 10.1586/era.09.6, 19374603.
13. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006, 242:151-167. 10.1016/j.canlet.2006.01.008, 16564617.
14. Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev 2006, 32:437-444. 10.1016/j.ctrv.2006.06.002, 16870349.
15. Thullberg M, Grasl-Kraupp B, Hogberg J, Garberg P. Changes in liver fatty acid-binding protein in rat enzyme-altered foci. Cancer Lett 1998, 128:1-10. 10.1016/S0304-3835(98)00040-8, 9652787.
16. Vanheule E, Geerts AM, Van Huysse J, Schelfhout D, Praet M, Van Vlierberghe H, De Vos M, Colle I. An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: relationship between fibrosis and angiogenesis. Int J Exp Pathol 2008, 89:419-432. 10.1111/j.1365-2613.2008.00608.x, 19134051.
17. Geerts AM, De Vriese AS, Vanheule E, Van Vlierberghe H, Mortier S, Cheung KJ, Demetter P, Lameire N, De Vos M, Colle I. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int 2006, 26:889-898. 10.1111/j.1478-3231.2006.01308.x, 16911473.
18. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, Langsteger W. The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT. Mol Imaging Biol 2009, 6:446-454.
19. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, Coleman RE. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001, 42:1805-1814.
20. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljarvi L, Talasniemi S, Ryynanen M, Riekkinen P. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett 1995, 187:79-82. 10.1016/0304-3940(95)11343-6, 7783963.
21. Chen B, Liu L, Castonguay A, Maronpot RR, Anderson MW, You M. Dose-Dependent Ras Mutation Spectra in N-Nitrosodiethylamine Induced Mouse-Liver Tumors and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Induced Mouse Lung-Tumors. Carcinogenesis 1993, 14:1603-1608. 10.1093/carcin/14.8.1603, 8353844.
22. Teoh NC, Dan YY, Swisshelm K, Lehman S, Wright JH, Haque J, Gu Y, Fausto N. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology 2008, 47:2078-2088. 10.1002/hep.22194, 18506893.
23. Frey S, Buchmann A, Bursch W, Schulte-Hermann R, Schwarz M. Suppression of apoptosis in C3H mouse liver tumors by activated Ha-ras oncogene. Carcinogenesis 2000, 21:161-166. 10.1093/carcin/21.2.161, 10657952.
24. Zimmers TA, Jin XL, Gutierrez JC, Acosta C, McKillop IH, Pierce RH, Koniaris LG. Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis. Journal of Cancer Research and Clinical Oncology 2008, 134:753-759. 10.1007/s00432-007-0336-4, 18210153.
25. Shiota G, Harada K, Ishida M, Tomie Y, Okubo M, Katayama S, Ito H, Kawasaki H. Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis 1999, 20:59-63. 10.1093/carcin/20.1.59, 9934850.
26. Hacker HJ, Mtiro H, Bannasch P, Vesselinovitch SD. Histochemical Profile of Mouse Hepatocellular Adenomas and Carcinomas Induced by a Single Dose of Diethylnitrosamine. Cancer Research 1991, 51:1952-1958.
27. Finnberg N, Stenius U, Hogberg J. Heterozygous p53-deficient (+/-) mice develop fewer p53-negative preneoplastic focal liver lesions in response to treatment with diethylnitrosamine than do wild-type (+/+) mice. Cancer Lett 2004, 207:149-155. 10.1016/j.canlet.2003.11.013, 15072823.
28. Matsumoto K, Suzuki K, Koike H, Okamura K, Tsuchiya K, Uchida T, Takezawa Y, Kobayashi M, Yamanaka H. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003, 23:4953-4958.
29. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, Zambruno G, D'Atri S. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. Journal of Investigative Dermatology 2000, 115:1000-1007. 10.1046/j.1523-1747.2000.00199.x, 11121133.
30. Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su YN, Chang KJ, Lee PH. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 2004, 213:73-82. 10.1016/j.canlet.2004.05.020, 15312686.
31. Donnini S, Machein MR, Plate KH, Weich HA. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J Pathol 1999, 189:66-71. 10.1002/(SICI)1096-9896(199909)189:1<66::AID-PATH390>3.0.CO;2-X, 10451490.
32. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG. Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 2005, 3:68. 10.1186/1477-7819-3-68, 1276823, 16223445.
33. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7:575-583. 10.1038/87904, 11329059.
34. Ho MC, Chen CN, Lee H, Hsieh FJ, Shun CT, Chang CL, Lai YT, Lee PH. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 2007, 250:237-249. 10.1016/j.canlet.2006.10.005, 17137709.